• Estimation of pharmacokinetic parameters, including variability | |
• Comparison of pharmacokinetic parameters with those of typical patients with normal kidney function (literature or sponsor data) or the appropriate reference population | |
• Quantification of the impact of changes in the prescribed Q e on the pharmacokinetic parameters of interest, and interpolation for flow rates not evaluated in this study | |
• Assessment of whether dosage adjustment is warranted in CRRT recipients | |
• If dosage adjustment is warranted, derivation of specific dosing recommendations for the studied conditions |